Search results for "portal vein"

showing 10 items of 83 documents

Hyperhomocysteinemia and the methylene tetrahydrofolate reductase C677T mutation in splanchnic vein thrombosis

2010

Introduction: The role that hyperhomocysteinemia (HH) and the C677T mutation in 5,10-methylenetetrahydrofolate reductase (MTHFR) play in splanchnic vein thrombosis (SVT) remains unclear due to this unusual thrombotic location. Objective: To analyse the possible association of HH with the C677T mutation in the MTHFR gene in SVT. Material and methods: We determined homocysteine levels and the C677T MTHFR mutation, along with classical cardiovascular risk factors, in 48 patients with SVT (18 Budd-Chiari syndrome, 11 mesenteric vein thrombosis, 19 portal vein thrombosis) and 84 controls. Results: In the univariate analysis, patients with SVT showed statistically higher homocysteine levels (P = …

medicine.medical_specialtyUnivariate analysisHyperhomocysteinemiabiologyHomocysteineCholesterolbusiness.industryHematologyGeneral Medicinemedicine.diseaseGastroenterologyPortal vein thrombosisSurgerychemistry.chemical_compoundVenous thrombosischemistrySplanchnic vein thrombosisInternal medicineMethylenetetrahydrofolate reductasemedicinebiology.proteinbusinessEuropean Journal of Haematology
researchProduct

Potential role of the neuropeptide CGRP in the induction of differentiation of rat hepatic portal vein wall.

2005

The media of the rat hepatic portal vein is composed of an internal circular muscular layer (CL) and an external longitudinal muscular layer (LL). These two perpendicular layers differentiate progressively from mesenchymal cells within the first month after birth. In this paper, we studied the development of calcitonin gene-related peptide (CGRP) innervation during post-natal differentiation of the vessel. We show that CGRP innervation is already present around the vessel at birth in the future adventitia but far from the lumen of the vessel. Progressively, CGRP immunoreactive fibers reached first LL then CL. CL by itself become only innervated at day 14 after birth. This corresponds to the…

medicine.medical_specialtyVascular smooth musclePhysiologyCalcitonin Gene-Related PeptideRecombinant Fusion ProteinsImmunocytochemistryMyocytes Smooth MuscleGene ExpressionCalcitonin gene-related peptideBiologyTransfectionBiochemistryMuscle Smooth VascularCell LineMuscular layerCellular and Molecular NeuroscienceMiceEndocrinologyInternal medicineAdventitiaMyosinmedicineAnimalsHumansRats WistarLuciferasesPromoter Regions GeneticBinding SitesMyosin Heavy ChainsPortal VeinNeuropeptidesAge FactorsCell DifferentiationImmunohistochemistryRatsEndocrinologymedicine.anatomical_structureLiverConnective TissueDesminHepatic portal veinRabbitsPeptides
researchProduct

Reperfusion of liver graft during transplantation: techniques used in transplant centres within Eurotransplant and meta-analysis of the literature

2013

Abstract: It remains unclear which liver graft reperfusion technique leads to the best outcome following transplantation. An online survey was sent to all transplant centres (n=37) within Eurotransplant (ET) to collect information on their technique used for reperfusion of liver grafts. Furthermore, a systematic review of all literature was performed and a meta-analysis was conducted based on patients' mortality, number of retransplantations and incidence of biliary complications, depending on the technique used. Of the 28 evaluated centres, 11 (39%) reported performing simultaneous reperfusion (SIMR), 13 (46%) perform initial portal vein reperfusion (IPR), 1 (4%) performs an initial hepati…

medicine.medical_specialtyVena cavamedicine.medical_treatmentPortal veinMedizin030230 surgeryRevascularizationVenovenous bypassretrograde reperfusionlaw.invention03 medical and health sciences0302 clinical medicineHepatic ArteryRandomized controlled triallawSurveys and QuestionnairesMedicineHumansRandomized Controlled Trials as TopicTransplantationbusiness.industryPortal Veinsimultaneous reperfusion3. Good healthSurgeryLiver TransplantationTransplantationLiver graftEuropeTreatment OutcomeMeta-analysisReperfusion030211 gastroenterology & hepatologyHuman medicineliver reperfusionbusinesssequential reperfusionLiver Circulation
researchProduct

Embolization with ethylene vinyl alcohol copolymer (Onyx®) for peripheral hemostatic and non-hemostatic applications: a feasibility and safety study

2018

International audience; Background: Onyx® is a liquid embolic agent, which is approved for the treatment of cerebral vascular lesions but still rarely used in peripheral interventional radiology. The goal of this study is to report the feasibility and safety of embolization with Onyx® for peripheral hemostatic and non-hemostatic endovascular procedures.Methods: Retrospective study of all consecutive patients who underwent visceral or peripheral embolization with Onyx® for hemostatic or non-hemostatic purpose in our department between May 2014 and November 2016. Demographic data, clinical presentation, underlying etiology, culprit vessel, endovascular procedure, pain during embolization, out…

medicine.medical_specialty[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentTranscatheter embolization030204 cardiovascular system & hematologyVialCulprit030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicineRadiology Nuclear Medicine and imagingEmbolizationTranscatheter embolizationmedicine.diagnostic_testbusiness.industryportal vein systemRetrospective cohort studyInterventional radiologyperipheral vascular lesions3. Good healthPeripheralSurgeryEtiologyhemorrhagebusinessethylene vinyl alcohol (EVOH) copolymer
researchProduct

Orthotope arterialisierte Lebertransplantation bei Ratten mit Stenttechnik der supra- und infrahepatischen v. cava

2003

The aim of this study was to establish a liver transplant model with a reduced warm ischemic period between cold preservation and completed anastomosis. Male brown Norway rats were used. A cuff was fixed in the portal vein, stents were inserted in the A. hepatica, the suprahepatic and infrahepatic v. cava and in the bile duct. After cross clamping of the recipient liver, another stent, occluded by a small pin, was introduced in the recipient suprahepatic v. cava. After ligation of this recipient suprahepatic caval stent the recipient liver was removed and the cold prepared donor liver was pushed forward along the pin and both suprahepatic stents of recipient and donor were connected. Then c…

medicine.medical_specialtybusiness.industryBile ductmedicine.medical_treatmentPortal veinStentAnastomosisSurgerymedicine.anatomical_structureCuffcardiovascular systemmedicineCold preservationcardiovascular diseasesLiving donor liver transplantationLigationbusiness
researchProduct

Chirurgische Therapie von Lebermetastasen kolorektaler Karzinome

2003

Resection is the only curative treatment of colorectal liver metastases proofed by a long-term follow-up. The operation is indicated if the metastases are completely removable with sufficient liver parenchyma remaining after resection and if the patient is fit for surgery. The resection is not indicated in cases with non resectable extrahepatic tumours and lymph node metastases distal the hepatoduodenal ligament. The postoperative mortality amounts to about 5 % and the 5-year-survival-rates range between 20 and 40 % depending on the selection of patients. Aims of new concepts of operative therapy are the improvement of resectability by preoperative portal vein embolization, the resection co…

medicine.medical_specialtybusiness.industryHepatoduodenal ligamentSurgeryResectionmedicine.anatomical_structurePortal vein embolizationmedicinePreoperative chemotherapySurgeryOperative therapySurgical treatmentbusinessLymph nodeLiver parenchymaZentralblatt für Chirurgie
researchProduct

Radiologic Evaluation of the Transplant Candidate

2003

Before a patient is placed on the waiting list for liver transplantation, a variety of screening procedures are performed, including laboratory tests and radiological procedures. One goal is to search for abnormalities that preclude liver transplantation. Another is to detect abnormalities that in some way will affect the operative procedure. The individual periopera- tive risk is evaluated by searching for pulmonary, cardiac, and renal changes.

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentPortal veinSplenic arteryLiver transplantationmedicine.diseasePortal vein thrombosisWaiting listRadiological weaponmedicine.arteryRadiologic EvaluationmedicineRadiologybusinessScreening procedures
researchProduct

Thrombophilic Genetic Factors PAI-1, MTHFRC677T, V Leiden 506Q, and Prothrombin 20210A in Noncirrhotic Portal Vein Thrombosis and Budd-Chiari Syndrom…

2013

Thrombophilic genetic factors PAI-1, MTHFRC677T, V Leiden 506Q, and Prothrombin 20210A were studied as risk factors in 235 Caucasian subjects: 85 patients with abdominal thrombosis (54 with portal vein thrombosis (PVT) and 31 with Budd-Chiari syndrome (BCS) without liver cirrhosis or hepatocellular carcinoma) and 150 blood bank donors. Seventy-five patients with PVT/BCS showed associated disease or particular clinical status (46 PVT/29 BCS): 37 myeloproliferative neoplasm (20 PVT/17 BCS), 12 abdominal surgery (10 PVT/2 BCS), 10 contraception or pregnancy (6 PVT/4 BCS), 7 abdominal acute disease (6 PVT/1 BCS), and 9 chronic disease (4 PVT/5 BCS); ten patients did not present any association …

medicine.medical_specialtyeducation.field_of_studyCirrhosisArticle Subjectbusiness.industryPopulationmedicine.diseaseGastroenterologyThrombosisPortal vein thrombosisSurgeryHepatocellular carcinomaInternal medicineRC666-701Budd–Chiari syndromemedicineClinical StudyDiseases of the circulatory (Cardiovascular) systemCardiology and Cardiovascular MedicinebusinesseducationMyeloproliferative neoplasmAbdominal surgeryInternational Journal of Vascular Medicine
researchProduct

Risk Factors Regarding Portal Vein Thrombosis in Chronic Liver Disease

2020

Abstract The portal vein thrombosis (PVT) is one of the most frequent vascular diseases of the liver, with a high rate of morbidity and mortality. The most common causes of the PVT are hepatic cirrhosis, hepatobiliary neoplasms, inflammatory and infectious abdominal diseases, and myeloproliferative syndromes.(1,2) The natural progress of the PVT has as a result portal hypertension which leads to splenomegaly and the formation of portosystemic collateral vessels, as well as gastroesophageal, duodenal and jejunal varices. Ultrasonography, especially Doppler ultrasound, is the most widely used imaging method to asses, supervise and diagnose PVT in patients with hepatopathies. The purpose of ac…

medicine.medical_specialtygenetic structuresbusiness.industryGeneral MedicineChronic liver diseasemedicine.diseasebehavioral disciplines and activitiesGastroenterologyPortal vein thrombosis03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicinemental disordersmedicine030211 gastroenterology & hepatologybusinesshuman activitiespsychological phenomena and processesActa Medica Transilvanica
researchProduct

Antithrombotic treatment and outcomes of splanchnic vein thrombosis in an international prospective registry: Results of 2-year follow-up

2014

Abstract Background: Little information is available on the long-term clinical outcome of patients with splanchnic vein thrombosis (SVT). We aimed to assess incidence rates of bleeding, recurrence, and mortality in a large prospective cohort of SVT patients after a 2-year follow-up. Methods: Consecutive SVT patients were enrolled in a multicenter international registry, from 2008 to 2012. Information was gathered on baseline characteristics, risk factors and therapeutic strategies. Clinical outcomes (major bleeding; vascular events, defined as venous or arterial thrombosis, and mortality) during follow-up were collected and reviewed by a Central Adjudication Committee. Major bleeding was de…

medicine.medical_specialtymedicine.drug_classliver cirrhosisImmunologyanticoagulant agentBiochemistrymaleInternal medicinedeathMedicinefollow upartery thrombosishumanRisk factorProspective cohort studythrombosisriskregisteranticoagulant therapybusiness.industryhematologyIncidence (epidemiology)pathogenesisAnticoagulantCell Biologymedicine.diseasebleedingThrombosismortalitySurgeryVenous thrombosissocietySplanchnic vein thrombosisvein thrombosisrisk factorsolidincidenceantivitamin KpatientbusinessAmericanFibrinolytic agentneoplasmhospitalizationportal vein
researchProduct